Existing biotech pipelines start with a target and hope for the desired clinical outcome. That might work for some indications, but not the brain.  

Psychiatric and neurological symptoms appear as changes in cognition, mood, and behavior. Clinical efficacy relies on regulating the neural control circuits behind them.

When models can’t output cognition, mood, and behavior, they can’t evaluate the success of CNS interventions. That’s why 73% of drugs fail in Phase II, where efficacy is first measured.

At Neuroblox we’ve spent the last 4 years building a platform that changes this paradigm: a multiscale, mechanistic neural circuit simulation engine that elicits cognition, mood and behavior, allowing scientists and clinicians to test brain interventions in silico.

Neuroblox provides the ability to design neurotherapeutic interventions intentionally, with an outcomes-first approach. Load your model, simulate as many interventions as needed, compare and refine, and select the approach that works best.

One Mind Accelerator | 2025 Cohort

Neuroblox, Inc.

Org chart

Teams

Offices

Neuroblox, Inc.

Org chart

Teams

Offices

Related companies